Share on StockTwits

Equities researchers at Piper Jaffray increased their target price on shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from $33.00 to $34.00 in a research report issued on Friday. Piper Jaffray’s price objective indicates a potential upside of 0.09% from the company’s current price.

FMS has been the subject of a number of other recent research reports. Analysts at Jefferies Group downgraded shares of Fresenius Medical Care AG & Co. from a “hold” rating to an “underperform” rating in a research note on Monday, June 30th. Analysts at Credit Suisse upgraded shares of Fresenius Medical Care AG & Co. from a “neutral” rating to an “outperform” rating in a research note on Thursday, June 26th. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. Fresenius Medical Care AG & Co. currently has an average rating of “Hold” and a consensus price target of $36.35.

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) traded down 1.53% on Friday, hitting $34.08. 83,838 shares of the company’s stock traded hands. Fresenius Medical Care AG & Co. has a 1-year low of $31.28 and a 1-year high of $37.01. The stock’s 50-day moving average is $33.39 and its 200-day moving average is $34.05. The company has a market cap of $20.554 billion and a price-to-earnings ratio of 19.22.

Fresenius Medical Care AG & Co. (NYSE:FMS) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.39 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.41 by $0.02. On average, analysts predict that Fresenius Medical Care AG & Co. will post $1.70 earnings per share for the current fiscal year.

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.